Next Phase Newsletter

A venture capital firm based in the US has significant experience working with regulatory agencies to gain product approval in both the FDA and CFDA systems. Since its establishment, the firm has invested in over 60 companies and continues to actively pursue life science opportunities with its third fund, targeting 8-10 new investments per year. The firm typically participates in Seed to Series B financing rounds with check sizes between $500K and $2M and will consider companies based in the USA, Europe, and Asia. 

The firm takes an opportunistic approach and will evaluate all early-stage opportunities in therapeutics, medical devices, diagnostics, and digital health, provided the technology is highly disruptive. The firm’s strongest focus and expertise lie in the medical device sector. Within therapeutics, the firm considers pre-clinical and Phase I assets, while in medical devices and diagnostics, it is open to all device classes, including 510(k) and PMA, at both development and clinical trial stages. The firm has invested in companies ranging from those with validated prototypes to those already generating profits prior to investment. 

The firm seeks to partner with companies led by experienced management teams, ideally serial entrepreneurs with proven track records. The firm can lead or co-invest but generally prefers to lead rounds in medical device companies and will typically take a board seat in those cases. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

The firm is a venture capital firm with offices in Western Europe. The firm makes equity investments in early- to late-stage therapeutics, diagnostics, and medical device companies, typically allocating between €2 million and €10 million per investment. The firm invests exclusively in companies based in Central and Western Europe and is actively seeking new opportunities. 

The firm is highly opportunistic within the life sciences sector, focusing on therapeutics, diagnostics, and medical devices while also maintaining interest in digital health. In therapeutics, the firm targets products that are in clinical trials or ready to enter Phase I. In medical devices, the firm seeks technologies that are CE Mark ready. While open across subsectors and indications, the firm does not invest in cosmetics or dental devices. The firm strongly favors companies developing products that address significant unmet medical needs. 

In digital health, the firm prefers products that either have or are pursuing regulatory approval to monitor or treat medical conditions with unmet needs, typically incorporating both hardware and software components. The firm does not invest in consumer or lifestyle health products. The firm’s prior investments include companies developing small molecule therapeutics for women’s health and diagnostics targeting autoimmune, allergic, ophthalmic, inflammatory, and liver diseases, as well as a medical device company treating prostate cancer. 

The firm typically acts as a lead or co-lead investor in most financing rounds and requires a board seat in its portfolio companies. The firm seeks to partner with companies that have strong and experienced management teams. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

The firm is a venture capital group based in New Jersey with a dedicated life sciences fund that invests primarily at the Seed stage. The fund typically commits around USD $1 million per company and is flexible in taking either a lead or co-investor role. Its geographic focus spans North America and Europe. 

Within life sciences, the fund targets therapeutics, medical technology, digital health, and biotech ecosystem companies that address age-related diseases such as cardiovascular disease, cancer, respiratory illnesses, dementia, Alzheimer’s, diabetes, and kidney disease. 

On the therapeutics side, the fund emphasizes “repair and replace” technologies, including regenerative medicine, gene therapy, and immunotherapy. In medtech, it is particularly interested in wearables, biosensors, and remote patient monitoring solutions. For digital health, the focus extends to AI-driven drug discovery and clinical trial optimization. Within the broader biotech ecosystem, areas of interest include bioprinting, biomaterials, and novel drug delivery systems. 

The firm seeks companies built on strong scientific foundations, offering innovative and scalable solutions. It values management teams with diverse expertise across science, business development, administration, and marketing. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A global pharmaceutical company headquartered in Europe with offices worldwide is specialized in rare diseases, respiratory conditions, and critical care. The firm actively seeks partnerships with early-stage companies and is open to a variety of collaboration structures, including co-development, SAFE agreements, in-licensing, and acquisitions, depending on the opportunity. 

Its Center for Open Innovation focuses on early-stage, pre-clinical assets, technologies, and digital or device-based healthcare solutions beyond the concept stage. Meanwhile, the business development and external innovation team engages with later-stage companies. With a strong international presence, the firm actively pursues opportunities across North America, Europe, and Asia. 

The firm concentrates on rare diseases, respiratory health, and critical care. While its main focus is on therapeutics, it also considers diagnostics, medical devices, and digital health opportunities. The Center for Open Innovation targets assets in the target identification and optimization phases (TRL 3–5/6), prioritizing technologies that are novel and transformative rather than incremental. 

Although the firm maintains defined therapeutic priorities, it remains open to adjacent or complementary innovation areas outside its existing pipeline. 

The firm values partners that emphasize environmental sustainability and social responsibility. Ideal management teams bring complementary expertise and a clear commitment to delivering  

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

The firm is a family office spin-off established in 2023 with offices in New York and Toronto, Canada. The firm invests globally through two complementary arms. The early-stage arm focuses on Pre-Seed and Seed opportunities in North America, typically writing first checks between USD $500k–2.5M into deeptech companies. The later-stage arm is dedicated exclusively to life sciences investments, with flexibility on check sizes and a global focus. While the firm does not typically lead rounds, it participates actively on a case-by-case basis. 

The early-stage strategy emphasizes deeptech companies—such as biotech, AI, space-tech, and medtech—while generally avoiding pure life sciences unless there is a strong technology angle, such as medical devices. The later-stage strategy targets Phase I–III ready drug assets. The firm is disease-agnostic, including orphan indications, but prefers companies addressing at least 5% of the population. Across both strategies, the firm favors companies pursuing FDA approval in the U.S. 

The firm does not have strict company or management team requirements, but appreciates teams with academic backgrounds or ties to universities. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology